Timothy Pluard

Timothy Pluard

UNVERIFIED PROFILE

Are you Timothy Pluard?   Register this Author

Register author
Timothy Pluard

Timothy Pluard

Publications by authors named "Timothy Pluard"

Are you Timothy Pluard?   Register this Author

29Publications

1180Reads

15Profile Views

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.

Lancet Oncol 2018 06 26;19(6):812-824. Epub 2018 Apr 26.

Breast Cancer Unit and Gynaecological Tumours, Ramon y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Baselga Oncology Institute, Quiron Group, Madrid and Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30147-5DOI Listing
June 2018

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

J Transl Med 2018 06 29;16(1):179. Epub 2018 Jun 29.

Northwest Biotherapeutics Inc., Bethesda, MD, USA.

View Article

Download full-text PDF

Source
https://translational-medicine.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s12967-018-1552-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026340PMC
June 2018

Ezh2, a novel target in detection and therapy of breast cancer.

Onco Targets Ther 2017 22;10:2685-2687. Epub 2017 May 22.

Midwest Biomedical Research Foundation, Kansas City Veterans Affairs Medical Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S138777DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449122PMC
May 2017

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).

J Clin Oncol 2017 Apr 3;35(10):1061-1069. Epub 2017 Jan 3.

Matthew J. Ellis and Chad J. Creighton, Baylor College of Medicine; Gildy Babiera and Kelly Hunt, MD Anderson Cancer Center, Houston; Gary Unzeitig, Doctor's Hospital of Laredo, Laredo; Marilyn Leitch, University of Texas Southwestern Campus, Dallas, TX; Vera J. Suman, Mayo Clinic, Rochester MN; Jeremy Hoog, Rodrigo Goncalves, Souzan Sanati, Katherine DeSchryver, Erika Crouch, Amy Brink, Mark Watson, Jingqin Luo, Yu Tao, Cynthia X. Ma, and D. Craig Allred, Washington University School of Medicine, St Louis; Timothy Pluard, St Lukes Hospital, Kansas City, MO; Michael Barnes, Roche Diagnostics, Mountain View; Laura Esserman, University of California San Francisco, San Francisco, CA; Mitchell Dowsett, Royal Marsden Hospital, London, UK; G. Thomas Budd, Cleveland Clinic; Paula Silverman, Case Western Reserve University, Cleveland OH; Eric Winer, Dana-Farber Cancer Institute, Boston MA; Lisa Carey, University of North Carolina, Chapel Hill; David Ota, Duke University, Durham, NC; Pat Whitworth, Nashville Breast Center, Nashville, TN; J. Michael Guenther, St Elizabeth Medical Center, Edgewood, KY; Zoneddy Dayao, University of New Mexico, Albuquerque, NM; and John A. Olson Jr, University of Maryland School of Medicine and Greenebaum Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.4406DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455353PMC
April 2017

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

J Clin Oncol 2015 Jan 4;33(1):13-21. Epub 2014 Aug 4.

William M. Sikov, Miriam Hospital and Alpert Medical School of Brown University, Providence, RI; Donald A. Berry, University of Texas MD Anderson Cancer Center, Houston, TX; Charles M. Perou and Lisa A. Carey, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill; Constance T. Cirrincione, Alliance Statistical Center, Durham; Charles S. Kuzma, Southeast Cancer Control Consortium, Winston-Salem, NC; Baljit Singh, New York University Medical Center; Elisa R. Port, Mount Sinai Medical Center; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Sara M. Tolaney, Mehra Golshan, Jennifer R. Bellon, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Timothy J. Pluard, Washington University-St Louis Medical Center, St Louis, MO; George Somlo, City of Hope Comprehensive Cancer Center, Duarte; Deborah Collyar, Patient Advocates in Research, Danville, CA; and Olwen M. Hahn, University of Chicago Medical Center, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.0572DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268249PMC
January 2015

Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.

J Clin Oncol 2014 Nov 6;32(32):3626-33. Epub 2014 Oct 6.

Cristina Saura and Javier Cortés, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona; Jose A. Garcia-Saenz, Hospital Clinico San Carlos; Miguel Martin, Hospital Gregorio Maranon, Universidad Complutense, Madrid, Spain; Binghe Xu, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China; Wael Harb, Horizon Medical Group, Lafayette, IN; Rebecca Moroose, University of Florida Health Cancer Center, Orlando, FL; Timothy Pluard, Washington University School of Medicine, St Louis, MO; Corinne Kiger, Pfizer Global Research and Development, Paris; Caroline Germa, Novartis Pharma, Rueil-Malmaison, France; Kongming Wang, Pfizer, Pearl River; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; and Sung-Bae Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.3809DOI Listing
November 2014

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.

Breast Cancer Res Treat 2013 May 19;139(1):145-53. Epub 2013 Apr 19.

Section of Breast Oncology, Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, P.O. Box 8056, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-013-2528-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517667PMC
May 2013

Phase II trial of temsirolimus in patients with metastatic breast cancer.

Breast Cancer Res Treat 2012 Nov 13;136(2):355-63. Epub 2012 Jan 13.

The University of Chicago Medical Center, 5841 South Maryland Ave., MC 2115, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-011-1910-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658119PMC
November 2012

Metastatic invasive breast cancer recurrence following curative-intent therapy for ductal carcinoma in situ.

J Surg Res 2012 Mar 23;173(1):10-5. Epub 2011 May 23.

Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jss.2011.04.058DOI Listing
March 2012